Summary & Overview
HCPCS Q5108: Pegfilgrastim-jmdb (Fulphila) 0.5 mg Injection
HCPCS Level II code Q5108 identifies injection of pegfilgrastim-jmdb (Fulphila), a biosimilar of pegfilgrastim, at a 0.5 mg dosage. This code matters nationally as pegfilgrastim and its biosimilars are commonly used to reduce the incidence of infection in patients receiving myelosuppressive chemotherapy, making accurate coding essential for clinical documentation, payment integrity, and biosimilar adoption monitoring. Key payers typically in scope for coverage and reimbursement include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn the clinical context for use of Q5108, typical places where the service is delivered, and the elements that influence billing and coverage determinations. The publication reviews common billing practices and benchmarks for biosimilar pegfilgrastim injections, summarizes relevant policy considerations that affect payer processing and prior authorization, and outlines coding nuances important for claims submission. Data limitations are noted where input fields are not provided. This overview is intended for national audiences including billing professionals, clinicians, and policy analysts seeking concise guidance on the use and administrative implications of HCPCS Level II code Q5108.
Billing Code Overview
HCPCS Level II code Q5108 represents an injection of pegfilgrastim-jmdb (Fulphila), biosimilar, 0.5 mg. This code is used to report administration of the biosimilar pegfilgrastim product in an injectable formulation.
Service Type: Therapeutic injection (biosimilar pegfilgrastim administration)
Typical Site of Service: Outpatient clinic, physician office, hospital outpatient department, or infusion center
Clinical & Coding Specifications
Clinical Context
A 58-year-old female undergoing adjuvant chemotherapy for stage II breast cancer receives supportive care to reduce the risk of chemotherapy-induced neutropenia. After chemotherapy administration in the outpatient oncology clinic, the oncology RN prepares a single subcutaneous dose of pegfilgrastim-jmdb (Fulphila) 0.5 mg using prefilled syringe or vial. The medication is administered in the clinic or provided as a same-day scheduled home health administration when a provider orders on-body injector placement. The clinical workflow includes verification of the chemotherapy regimen and cycle day, assessment of absolute neutrophil count and clinical contraindications, obtaining patient consent, documentation of lot number and expiration, administration with standard injection technique, patient observation for immediate adverse reactions, and recording of billing details.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default placeholder (not a standard CMS modifier) | Use only if required by payer-specific billing systems when no other modifier applies. |
11 | Professional component | When billing for the professional component of a service if a split of technical/professional services applies (rare for drugs). |